Brandon Capital portfolio

ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

ENA Respiratory won a A$2.98 million grant from incubator Biointelect Venturer's first funding round, supporting a Phase Ib Australian trial of its INNA-051 nasal spray in asthma patients.

Under Brandon Capital portfolio ·leads this story in the feed

Brandon Capital portfolio company AdvanCell raises US$315 million to accelerate next generation of targeted alpha therapies

AdvanCell has closed a US$315 million Series D round co-led by Ally Bridge Group and Alpha Wave to advance its prostate cancer therapy into Phase 3 and expand manufacturing; Brandon Capital also took part.

Under Brandon Capital portfolio ·leads this story in the feed

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.

Reinventing the fight against chronic lung infections

Brandon Capital's blog profiles Respirion, interviewing founders Barry Clements and Matt Callahan plus investment manager Helga Mikkelsen about the company's inhaled cystic fibrosis therapy, now in a Phase 2a trial.

ENA Respiratory Appoints Melissa Faris to Board

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

Melbourne biotech Aravax, developer of the peanut allergy immunotherapy PVX108, adds former ALK-Abello chief Carsten Hellmann and ex-Aimmune commercial head Andrew Oxtoby to its board ahead of Phase 3.

Lumonus inks joint venture with NY cancer centre to scale AI oncology

Lumonus, a GenesisCare spinout chaired by Merrick Howes, is partnering with a New York cancer centre to co-develop automated radiotherapy planning tools.

Denteric Announces FDA IND Clearance for GPV381, a First-in-Class Therapeutic Vaccine Targeting Gingipain-Driven Inflammation in Periodontitis

Melbourne biotech Denteric has won US regulatory clearance to trial GPV381, a vaccine-style therapy targeting the bacteria behind gum disease, with a Phase 2 study in the United States to follow.

Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClotTM rapid serum blood collection tube technology in Japan

Q-Sera's rapid-clotting blood tube technology has gone to market in Japan via Terumo's VenoJect II launch; the Melbourne startup's backers include MRCF, Uniseed and the UniQuest Extension Fund.

ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.

ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Clinical Studies of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

Antiviral developer ENA Respiratory closed a US$22.4m (AU$34m) Series B, backed by Brandon Capital, Uniseed, Stoic, the Gates Foundation and Flu Lab, to fund Phase II studies of its weekly nasal spray.

Under Brandon Capital portfolio ·leads this story in the feed

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$430 m

Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.

PolyActiva Secures $40M in Series C Financing to Advance PREZIA™ Platform Technology and Drive Innovation in Sustained Ocular Drug Delivery

Melbourne eye-disease biotech PolyActiva has banked a Series C round to advance its implant programme, with the national reconstruction fund and publisher Brandon Capital among the syndicate.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer

Melbourne pharmaceutical developer ENA Respiratory hires two international drug-development experts as strategic advisors as it readies its nasal antiviral candidate INNA-051 for US Phase II trials.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

FDA Approves WiSE® System, World's First and Only Leadless Left Ventricular Endocardial Pacing (LVEP) Device for CRT

EBR Systems has won US regulatory approval for its WiSE implant, the first leadless device for a form of cardiac resynchronization therapy, which the CEO frames as the end of a 22-year development phase.

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Vaxxas has filled its 258-person Phase I trial of a needle-free avian flu vaccine patch, run under a US$28.5 million US government contract; the post also recounts the company's early backing.

Under Brandon Capital portfolio ·leads this story in the feed

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Flu Lab has invested five million US dollars in Melbourne-based ENA Respiratory to advance Phase II testing of INNA-051, a weekly nasal powder that boosts innate antiviral immunity.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.

Also Startup Daily·SmartCompany·Forbes Australia

Vaxxas Named Stage Winner of United States' BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia

Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx

Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.

Also Brandon BioCatalyst portfolio

Under GBS Ventures ·leads this story in the feed

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.

Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation

Brandon Capital has reached an initial close of A$270 million on its sixth life sciences fund, backed by superannuation funds HESTA and Hostplus, with the vehicle remaining open to further investors.

Under Brandon Capital portfolio ·leads this story in the feed

Respirion offers hope for people living with cystic fibrosis

A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.

Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential

CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.

Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org

ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator

ENA Respiratory says the US FDA has cleared its IND application for INNA-051, paving the way for an Australian Phase 1b trial of the dry powder antiviral from mid-2024.

Under Brandon Capital portfolio ·leads this story in the feed

Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy

Aravax has wrapped up its US$42.2 million Series B, adding five new investors to early backers Brandon Capital and Tenmile, to fund expanded Phase 2 trials of its peanut allergy drug PVX108.

Under Breakthrough Victoria ·leads this story in the feed

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.

Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst

Cicada Innovations is opening a health-tech incubator at Sydney's Westmead precinct with NSW government grant backing, working with Brandon Capital and Brandon BioCatalyst to help researchers commercialise medical discoveries.

State Government Backs OncoRes Medical with Funding to Manufacture Digital Cancer ImagingDevice in WA

OncoRes Medical has received a $3 million WA government grant to manufacture its surgical cancer-imaging device locally, its latest funding after a 2022 Series A2 and earlier state and federal grants.

Also Brandon BioCatalyst portfolio·Startup News (WA)

Under Brandon BioCatalyst portfolio ·leads this story in the feed

Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine

Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.

Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer

Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.

Nineteen groundbreaking biotech projects selected for national incubator

CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.

EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation

Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.

Also Brandon BioCatalyst portfolio

Under Brandon BioCatalyst portfolio ·leads this story in the feed

Healthcare Veteran, Zach Henderson to lead Global Kinetics as CEO

Global Kinetics, a Melbourne-based digital neurology company, names Zach Henderson its chief executive; Leighton Read shifts to non-executive chair and BioScience Managers' David Atkins joins the board.

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access

Vaxxas partners with CEPI, which will fund preclinical testing of its needle-free vaccine patch for mRNA vaccines, work that could remove cold-storage needs and widen global access to such vaccines.

Also Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing

ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

Antiviral developer ENA Respiratory has received a multi-million-dollar US defence agreement to advance its intranasal antiviral candidate, with earlier backing from Brandon Capital-managed funds, the Minderoo Foundation and Uniseed.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

Billionaires Andrew and Nicola Forrest take aim at peanut allergy

Brandon Capital and the Forrest family's healthcare venture have committed to a Series B in biotech Aravax, funding Phase 2 trials of its peanut allergy immunotherapy PVX108.

Under Brandon Capital portfolio ·leads this story in the feed

Aravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile

Aravax has begun its Series B with a US$20 million investment from Brandon Capital and Tenmile, funding Phase 2 trials of its peanut allergy immunotherapy PVX108 while it seeks further capital.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Forbes Australia·Techboard·Business News Australia

Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Biotech startup Entact Bio has launched with an $81 million Series A funding its Encompass platform, which designs molecules that enhance protein function, backed by Qiming Venture Partners USA, venBio Partners and others.

Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate

Vaxxas completed a financing round led by OneVentures and UniQuest to advance needle-free vaccine programs and manufacturing, with the new funds leveraging large committed non-dilutive government and global health support.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

QUE Oncology's non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet

Brandon Capital's blog covers QUE Oncology's Phase II Q-122 results in The Lancet, showing reduced hot flushes and night sweats in breast cancer patients on endocrine therapy.

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.

First Aussies to get needle-free COVID-19 vaccine patch

Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.

First in-human use of OncoRes Medical's cancer imaging technology successful

OncoRes Medical's handheld breast cancer imaging device performed well in its first patient study, with results published in a peer-reviewed journal; the Perth medtech's earlier $9.5m raise and $3m grant are noted.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

$16m cash injection to progress first-in-class therapy for inflammation and fibrosis

Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.

Also Brandon BioCatalyst portfolio·Startup Daily

Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort

Azura Ophthalmics won a CUREator grant to fund a two-stage study of its AZR-MD-001 candidate for contact lens discomfort, extending pilot research conducted with UNSW; the incubator program is run by Brandon BioCatalyst.

Also Brandon BioCatalyst portfolio

Australia's first national biotech incubator announces round one funding to support life science breakthroughs

The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

CUREator, the national biotechnology incubator, backs 23 start ups

Biotech incubator CUREator has distributed 17.4 million dollars in inaugural grants to 23 medical startups nationwide, including Phrenix and RAGE Biotech, to ready them for commercial backing.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board

Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.

Over $15m invested in world-leading cancer immunotherapy

Auckland University spinout TamoRx has secured NZ$15.25 million to develop a new cancer immunotherapy, in a round led by Brandon Capital alongside the university's Inventors' Fund, with a Callaghan Innovation grant included.

Australian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials

Perth medtech OncoRes Medical raised $12.5 million for its breast cancer imaging system — a $9.5 million Series A2 co-led by Brandon Capital plus a $3 million CRC-P grant — and appointed a new VP of R&D.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

Brandon Capital reports that ENA Respiratory has become the first Australian company chosen for BLUE KNIGHT, a JLABS-BARDA initiative supporting its intranasal broad-spectrum antiviral spray INNA-051.

Aravax appoints Dr Brett Haumann to Board of Directors

Clinical-stage biotech Aravax has added pharma veteran Dr Brett Haumann, formerly of ReViral, Theravance, GSK and Aimmune, as a non-executive director ahead of a Phase 2 study of its peanut allergy therapy PVX108.

Australian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions

Biotech startup Ankere Therapeutics has launched with a ten million dollar seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies from Monash and UniSA research.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

Boosting product confidence of a world-leading RNA therapeutics start-up

Case study on how CSIRO's bioinformatics teams independently validated the cancer-target findings of Amaroq Therapeutics, a New Zealand biotech whose $14m seed round was funded by the Brandon Capital-managed MRCF and others.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

ENA Respiratory has begun a Phase 2a influenza-challenge trial in the UK of its INNA-051 antiviral nasal spray; the article also recalls its Series A backing by Brandon Capital, Minderoo Foundation and Uniseed.

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

Aravax clears its US FDA application to trial its peanut-allergy immunotherapy PVX108 in Phase 2 studies across two countries, and adds a prominent food-allergy paediatric specialist to its scientific advisory board.

Silicon Valley pacemaker hopes to capture Aussie hearts with ASX float

US-based leadless pacemaker maker EBR Systems has listed on the ASX, backed by local investors and spurning SPAC offers; the piece also recalls Blackbird's earlier investment in ultrasound-robot startup Vexev.

Under Brandon BioCatalyst portfolio ·leads this story in the feed

Life science researchers and entrepreneurs encouraged to seek investment from new $40m Australian biotech incubator

The MRCF, managed by publisher Brandon Capital, has launched a government-funded national biotech incubator with committed funding, and appointed a new Head of Operations, with applications now open for its first intake.